CAJ | 학술논문

目的研究贝伐珠单抗(bevacizumab,Bev)联合化疗治疗转移性结直肠癌的近期疗效和安全性.方法对43例接受贝伐珠单抗联合化疗治疗的晚期结直肠癌患者进行回顾分析,评价联合治疗的近期疗效及不良反应.结果 43例患者中部分缓解(PR)17例,疾病稳定(SD)19例,疾病进展(PD)7例;中位无进展生存(PFS)为10.3个月.3～4度不良反应主要为白细胞和粒细胞减少及恶心、呕吐.与贝伐珠单抗相关的不良反应为蛋白尿、高血压、鼻出血、经血增加、肠道出血、肠穿孔及静脉血栓等.结论贝伐珠单抗联合化疗治疗晚期结直肠癌近期疗效较好,不良反应可耐受,远期疗效有待进一步观察.
목적 연구패벌주단항(bevacizumab,Bev)연합화료치료전이성결직장암적근기료효화안전성.방법 대43례접수패벌주단항연합화료치료적만기결직장암환자진행회고분석,평개연합치료적근기료효급불량반응.결과 43례환자중부분완해(PR)17례,질병은정(SD)19례,질병진전(PD)7례;중위무진전생존(PFS)위10.3개월.3～4도불량반응주요위백세포화립세포감소급악심、구토.여패벌주단항상관적불량반응위단백뇨、고혈압、비출혈、경혈증가、장도출혈、장천공급정맥혈전등.결론 패벌주단항연합화료치료만기결직장암근기료효교호,불량반응가내수,원기료효유대진일보관찰.
Objective To investigate the efficacy and safety of Bevacizumab (Bev) combined with chemotherapy protocols in the patients with metastatic colorectal cancer (mCRC).Methods 43 patients with mCRC were treated with Bev combined with various of chemotherapy protocols.The efficacy was assessed based on Response Evaluation Criterion for Solid Tumors (RECIST),and the adverse events were evaluated according to National Cancer Institute-Common Toxicity Criterion for Adverse Events (NCI-CTCAE) 3.0.Results The data of 43 patients (16 males and 27 females) were analyzed.17 patients achieved partial remission (PR),19 patients stable disease (SD) and 7 patients progressive disease (PD).The median progression-free survival (PFS) time was 10.3 months.The major of 3-4 adverse events included leucocytopenia,neutropenic febrile,and nausea/vomiting.Bey-associated adverse events were proteinuria,hypertension,rhinorrhagia,hemorrhagic hemorrhoid,menstrual blood increased,gastrointestinal perforation and venous thrombosis.Conclusions Bey combined with various chemotherapy protocols is more effective for patients with mCRC.Most patients can tolerate the side effects of the combined treatment.The long-term effects of the combined treatment need to be followed up.